A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting

Trial Profile

A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin; Clopidogrel; Ticagrelor; Warfarin
  • Indications Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions; Registrational
  • Acronyms RE-DUAL PCI
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Aug 2017 Primary endpoint (Time to first International Society of Thrombosis and Haemostasis Major Bleeding Event or Clinically Relevant Non Major Bleeding Event) has been met, according to the results published in the New England Journal of Medicine
    • 27 Aug 2017 Results published in the New England Journal of Medicine
    • 27 Aug 2017 Results published in a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top